{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:39:31Z","timestamp":1790437171909,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T00:00:00Z","timestamp":1657324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.omtm.2022.07.005","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T16:40:51Z","timestamp":1657557651000},"page":"279-293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse"],"prefix":"10.1016","volume":"26","author":[{"given":"Nicolas","family":"Wein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana A.","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Vulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabatha R.","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma C.","family":"Frair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne J.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liubov V.","family":"Gushchina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila F.","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanarajan","family":"Rajakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Flanigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2022.07.005_bib1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2022.07.005_bib2","first-page":"121","article-title":"Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients","volume":"31","author":"Passamano","year":"2012","journal-title":"Acta Myol."},{"key":"10.1016\/j.omtm.2022.07.005_bib3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/bmj.2.363.541","article-title":"The pathology of paralysis with muscular degeneration (paralysie myosclerotique), or paralysis with apparent hypertrophy","volume":"2","author":"Duchenne","year":"1867","journal-title":"Br. Med. J."},{"key":"10.1016\/j.omtm.2022.07.005_bib4","doi-asserted-by":"crossref","first-page":"e0135189","DOI":"10.1371\/journal.pone.0135189","article-title":"DMD mutations in 576 dystrophinopathy families: a step forward in genotype-phenotype correlations","volume":"10","author":"Juan-Mateu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2022.07.005_bib5","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2022.07.005_bib6","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/nm.3628","article-title":"Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice","volume":"20","author":"Wein","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2022.07.005_bib7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/0968-0004(89)90290-9","article-title":"Dystrophin, the protein product of the Duchenne\/Becker muscular dystrophy gene","volume":"14","author":"Monaco","year":"1989","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.omtm.2022.07.005_bib8","first-page":"97","article-title":"Use of adeno-associated virus as a general transduction vector for mammalian cells","volume":"158","author":"Muzyczka","year":"1992","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.omtm.2022.07.005_bib9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ymthe.2004.09.011","article-title":"Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective","volume":"10","author":"Carter","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.07.005_bib10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","article-title":"AAV-mediated gene therapy for research and therapeutic purposes","volume":"1","author":"Samulski","year":"2014","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.omtm.2022.07.005_bib11","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.07.005_bib12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nm0302-253","article-title":"Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy","volume":"8","author":"Harper","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2022.07.005_bib13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.nmd.2018.06.009","article-title":"Personalized gene and cell therapy for duchenne muscular dystrophy","volume":"28","author":"Barthelemy","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2022.07.005_bib14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.pcl.2015.03.008","article-title":"Genetics and emerging treatments for Duchenne and Becker muscular dystrophy","volume":"62","author":"Wein","year":"2015","journal-title":"Pediatr. Clin. North. Am"},{"key":"10.1016\/j.omtm.2022.07.005_bib15","doi-asserted-by":"crossref","first-page":"e15858","DOI":"10.1097\/MD.0000000000015858","article-title":"Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy","volume":"98","author":"Alfano","year":"2019","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.omtm.2022.07.005_bib16","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1073\/pnas.95.9.4929","article-title":"Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs","volume":"95","author":"Gorman","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2022.07.005_bib17","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1093\/hmg\/8.13.2415","article-title":"Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human beta-thalassemic mutations","volume":"8","author":"Suter","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2022.07.005_bib18","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1093\/hmg\/dds082","article-title":"Rescue of severely affected dystrophin\/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping","volume":"21","author":"Goyenvalle","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2022.07.005_bib19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/gt.2012.38","article-title":"MRI roadmap-guided transendocardial delivery of exon-skipping recombinant adeno-associated virus restores dystrophin expression in a canine model of Duchenne muscular dystrophy","volume":"20","author":"Barbash","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2022.07.005_bib20","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/mt.2011.264","article-title":"Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping","volume":"20","author":"Bish","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.07.005_bib21","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1038\/mt.2012.181","article-title":"Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping","volume":"20","author":"Vulin","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.07.005_bib22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtm.2022.07.005_bib23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.nmd.2009.08.010","article-title":"DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy","volume":"19","author":"Flanigan","year":"2009","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2022.07.005_bib24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/humu.20913","article-title":"DMD exon 1 truncating point mutations: amelioration of phenotype by alternative translation initiation in exon 6","volume":"30","author":"Gurvich","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtm.2022.07.005_bib25","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.nmd.2015.08.005","article-title":"The first exon duplication mouse model of Duchenne muscular dystrophy: a tool for therapeutic development","volume":"25","author":"Vulin","year":"2015","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2022.07.005_bib26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.omtm.2021.03.014","article-title":"Pre-clinical dose-escalation studies establish a therapeutic range for U7snRNA-mediated DMD exon 2 skipping","volume":"21","author":"Simmons","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2022.07.005_bib27","first-page":"1346","article-title":"Absence of significant off-target splicing variation with a U7snRNA vector targeting DMD exon 2 duplications","volume":"32","author":"Wein","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2022.07.005_bib28","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1089\/hum.2020.286","article-title":"Lack of toxicity in nonhuman primates receiving clinically relevant doses of an AAV9.U7snRNA vector designed to induce DMD exon 2 skipping","volume":"32","author":"Gushchina","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2022.07.005_bib29","article-title":"Automated immunofluorescence analysis for sensitive and precise dystrophin quantification in muscle biopsies","author":"Vetter","year":"2021","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.omtm.2022.07.005_bib30","doi-asserted-by":"crossref","first-page":"9142","DOI":"10.1073\/pnas.93.17.9142","article-title":"Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy","volume":"93","author":"Chang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2022.07.005_bib31","doi-asserted-by":"crossref","first-page":"15000","DOI":"10.1073\/pnas.192571199","article-title":"Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle","volume":"99","author":"Haslett","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2022.07.005_bib32","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtm.2022.07.005_bib33","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2022.07.005_bib34","doi-asserted-by":"crossref","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production","volume":"90","author":"Charleston","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2022.07.005_bib35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nm1345","article-title":"Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology","volume":"12","author":"Alter","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2022.07.005_bib36","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/ana.21627","article-title":"Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs","volume":"65","author":"Yokota","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2022.07.005_bib37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13395-017-0124-z","article-title":"The golden retriever model of Duchenne muscular dystrophy","volume":"7","author":"Kornegay","year":"2017","journal-title":"Skelet Muscle"},{"key":"10.1016\/j.omtm.2022.07.005_bib38","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/mt.2013.121","article-title":"AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy","volume":"21","author":"Le Hir","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.07.005_bib39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3233\/JND-180357","article-title":"Report of a TREAT-NMD\/world duchenne organisation meeting on dystrophin quantification methodology","volume":"6","author":"Aartsma-Rus","year":"2019","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.omtm.2022.07.005_bib40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.nmd.2017.11.007","article-title":"Low-level dystrophin expression attenuating the dystrophinopathy phenotype","volume":"28","author":"Waldrop","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2022.07.005_bib41","article-title":"Phenotypic spectrum of dystrophinopathy due to duchenne muscular dystrophy\u00a0exon 2 duplications","author":"Zambon","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2022.07.005_bib42","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.omtn.2017.12.008","article-title":"RNA-seq analysis of an antisense sequence optimized for exon skipping in duchenne patients reveals No off-target effect","volume":"10","author":"Domenger","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2022.07.005_bib43","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1126\/science.1104297","article-title":"Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping","volume":"306","author":"Goyenvalle","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.omtm.2022.07.005_bib44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-1-61737-982-6_5","article-title":"Monitoring murine skeletal muscle function for muscle gene therapy","volume":"709","author":"Hakim","year":"2011","journal-title":"Methods Mol. Biol."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050122000973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050122000973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:13:07Z","timestamp":1714695187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050122000973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":44,"alternative-id":["S2329050122000973"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2022.07.005","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2022.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}]}}